Interleukin-32α Inactivates JAK2/STAT3 Signaling and Reverses Interleukin-6-induced Epithelial-mesenchymal Transition, Invasion, and Metastasis in Pancreatic Cancer Cells

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2016 Jul 30

PMID 27471397

Citations 25

Authors

Jingfeng Chen

Silu Wang

Jiadong Su

Guanyu Chu

Heyi You

Zongjing Chen

Hongwei Sun

Bicheng Chen

Mengtao Zhou

Affiliations

Soon will be listed here.

Abstract

Interleukin (IL)-32 is a newly discovered cytokine that has multifaceted roles in inflammatory bowel disease, cancer, and autoimmune diseases and participates in cell apoptosis, cancer cell growth inhibition, accentuation of inflammation, and angiogenesis. Here, we investigated the potential effects of IL-32α on epithelial-mesenchymal transition, metastasis, and invasion, and the JAK2/STAT3 signaling pathway in pancreatic cancer cells. The human pancreatic cancer cell lines PANC-1 and SW1990 were used. Epithelial-mesenchymal transition-related markers, including E-cadherin, N-cadherin, Vimentin, Snail, and Zeb1, as well as extracellular matrix metalloproteinases (MMPs), including MMP2, MMP7, and MMP9, were detected by immunofluorescence, Western blotting, and real-time polymerase chain reaction. The activation of JAK2/STAT3 signaling proteins was detected by Western blotting. Wound healing assays, real-time polymerase chain reaction, and Western blotting were performed to assess cell migration and invasion. The effects of IL-32α on the IL-6-induced activation of JAK2/STAT3 were also evaluated. In vitro, we found that IL-32α inhibits the expressions of the related markers N-cadherin, Vimentin, Snail, and Zeb1, as well as JAK2/STAT3 proteins, in a dose-dependent manner in pancreatic cancer cell lines. Furthermore, E-cadherin expression was increased significantly after IL-32α treatment. IL-32α downregulated the expression of MMPs, including MMP2, MMP7, and MMP9, and decreased wound healing in pancreatic cancer cells. These consistent changes were also found in IL-6-induced pancreatic cancer cells following IL-32α treatment. This study showed that reversion of epithelial-mesenchymal transition, inhibition of invasiveness and metastasis, and activation of the JAK2/STAT3 signaling pathway could be achieved through the application of exogenous IL-32α.

Citing Articles

MALAT1/miR-582-5p/GALNT1/MUC1 axis modulates progression of AML leukemia stem cells by regulating JAK2/STAT3 pathway.

Li S, Gao R, Han X, Wang K, Kang B, Ma X Ann Hematol. 2024; 103(12):5273-5283.

PMID: 39428449 DOI: 10.1007/s00277-024-06043-w.

Pan-cancer analysis reveals IL32 is a potential prognostic and immunotherapeutic biomarker in cancer.

Han F, Ma J Sci Rep. 2024; 14(1):8129.

PMID: 38584169 PMC: 10999427. DOI: 10.1038/s41598-024-58550-5.

Role of interleukin‑32 in cancer progression (Review).

Meng D, Dong H, Wang C, Zang R, Wang J Oncol Lett. 2024; 27(2):54.

PMID: 38192653 PMC: 10773214. DOI: 10.3892/ol.2023.14187.

Characterization of residual cancer by comparison of a pair of organoids established from a patient with esophageal squamous cell carcinoma before and after neoadjuvant chemotherapy.

Fuchino T, Kurogi S, Tsukamoto Y, Shibata T, Fumoto S, Fujishima H Hum Cell. 2024; 37(2):491-501.

PMID: 38184488 DOI: 10.1007/s13577-023-01020-3.

Molecular profile of metastasis, cell plasticity and EMT in pancreatic cancer: a pre-clinical connection to aggressiveness and drug resistance.

Guo Z, Ashrafizadeh M, Zhang W, Zou R, Sethi G, Zhang X Cancer Metastasis Rev. 2023; 43(1):29-53.

PMID: 37453022 DOI: 10.1007/s10555-023-10125-y.

References

Humphris J, Johns A, Simpson S, Cowley M, Pajic M, Chang D . Clinical and pathologic features of familial pancreatic cancer. Cancer. 2014; 120(23):3669-75. DOI: 10.1002/cncr.28863. View

Nold-Petry C, Rudloff I, Baumer Y, Ruvo M, Marasco D, Botti P . IL-32 promotes angiogenesis. J Immunol. 2013; 192(2):589-602. PMC: 4007307. DOI: 10.4049/jimmunol.1202802. View

Huang S . Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res. 2007; 13(5):1362-6. DOI: 10.1158/1078-0432.CCR-06-2313. View

Lesina M, Kurkowski M, Ludes K, Rose-John S, Treiber M, Kloppel G . Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011; 19(4):456-69. DOI: 10.1016/j.ccr.2011.03.009. View

Lamy S, Akla N, Ouanouki A, Lord-Dufour S, Beliveau R . Diet-derived polyphenols inhibit angiogenesis by modulating the interleukin-6/STAT3 pathway. Exp Cell Res. 2012; 318(13):1586-96. DOI: 10.1016/j.yexcr.2012.04.004. View

Fukuda A, Wang S, Morris 4th J, Folias A, Liou A, Kim G . Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. Cancer Cell. 2011; 19(4):441-55. PMC: 3075548. DOI: 10.1016/j.ccr.2011.03.002. View

Kim S, Han S, Azam T, Yoon D, Dinarello C . Interleukin-32: a cytokine and inducer of TNFalpha. Immunity. 2005; 22(1):131-42. DOI: 10.1016/j.immuni.2004.12.003. View

Huang C, Yang G, Jiang T, Zhu G, Li H, Qiu Z . The effects and mechanisms of blockage of STAT3 signaling pathway on IL-6 inducing EMT in human pancreatic cancer cells in vitro. Neoplasma. 2011; 58(5):396-405. DOI: 10.4149/neo_2011_05_396. View

Kohler I, Bronsert P, Timme S, Werner M, Brabletz T, Hopt U . Detailed analysis of epithelial-mesenchymal transition and tumor budding identifies predictors of long-term survival in pancreatic ductal adenocarcinoma. J Gastroenterol Hepatol. 2015; 30 Suppl 1:78-84. DOI: 10.1111/jgh.12752. View

10.

Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y . Interactions between IL-32 and tumor necrosis factor alpha contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther. 2006; 8(6):R166. PMC: 1794509. DOI: 10.1186/ar2074. View

11.

Park J, Choi S, Lee J, Lee M, Nam E, Jeong A . Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway. Cell Oncol (Dordr). 2013; 36(6):493-503. DOI: 10.1007/s13402-013-0154-4. View

12.

Oh J, Cho M, Kim J, Lee S, Kim H, Park E . IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene. 2011; 30(30):3345-59. PMC: 3145890. DOI: 10.1038/onc.2011.52. View

13.

Chen Q, Carroll H, Gadina M . The newest interleukins: recent additions to the ever-growing cytokine family. Vitam Horm. 2006; 74:207-28. DOI: 10.1016/S0083-6729(06)74008-0. View

14.

Yang J, Liao X, Agarwal M, Barnes L, Auron P, Stark G . Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007; 21(11):1396-408. PMC: 1877751. DOI: 10.1101/gad.1553707. View

15.

Liu R, Zeng Y, Lei Z, Wang L, Yang H, Liu Z . JAK/STAT3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells. Int J Oncol. 2014; 44(5):1643-51. DOI: 10.3892/ijo.2014.2310. View

16.

Deryugina E, Quigley J . Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta. 2009; 1803(1):103-20. PMC: 2824055. DOI: 10.1016/j.bbamcr.2009.09.017. View

17.

Shaul Y, Freinkman E, Comb W, Cantor J, Tam W, Thiru P . Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014; 158(5):1094-1109. PMC: 4250222. DOI: 10.1016/j.cell.2014.07.032. View

18.

Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L . Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine. 2013; 65(1):24-32. DOI: 10.1016/j.cyto.2013.09.017. View

19.

Yu H, Kortylewski M, Pardoll D . Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2006; 7(1):41-51. DOI: 10.1038/nri1995. View

20.

Bramhall S . Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition. J Hepatobiliary Pancreat Surg. 1999; 5(4):392-401. DOI: 10.1007/s005340050063. View